Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sentiss Pharma Private Limited currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action across its active filings. This specific workload is concentrated under 1 examiner, MITCHELL, EDWIN COLEMAN, who is responsible for 1 pending action. This indicates a centralized prosecution path where all current interactions with the USPTO are handled by 1 individual. The focus on 1 examiner suggests that the company's current legal strategy is not diversified across multiple points of contact within the patent office at this time.
The organizational structure of these filings is similarly streamlined, as the portfolio is currently assigned to 1 distinct art unit. This matches the count of 1 distinct examiner involved in the process. For practitioners, this means that the entirety of the company's current office action responses are directed toward the busiest examiner within this 1 art unit. The lack of variety in art units or examiners suggests that the current legal strategy is confined to a specific technical niche. MITCHELL, EDWIN COLEMAN holds the 1 pending action currently recorded for the firm, making their specific examination style the primary factor in the company's current prosecution outcomes.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MITCHELL, EDWIN COLEMAN | 1 | 32.1% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270389 | MYDRIATIC AND ANTI-MUSCARINIC AGENT COMPOSITION FOR OPHTHALMIC USE | MITCHELL, EDWIN COLEMAN | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270389 | MYDRIATIC AND ANTI-MUSCARINIC AGENT COMPOSITION FOR OPHTHALMIC USE | MITCHELL, EDWIN COLEMAN | 56d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270389 | MYDRIATIC AND ANTI-MUSCARINIC AGENT COMPOSITION FOR OPHTHALMIC USE | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Non-Final OA | 56d | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSentiss Pharma Private Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Edwin Coleman Mitchell has the most, with 1 of Sentiss Pharma Private Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
